PTPN11 and neoplasm: Compared to the SHP2-NC group, the SHP2-mimic group displayed a significant reduction in tumor cross-sectional area; compared to the SHP2-NC+Sindilizumab group, the SHP2-mimic+Sindilizumab group had a significantly reduced tumor cross-sectional area.